Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Investing.com -- Pharvaris N.V. (NASDAQ:PHVS) stock fell 9.6% after the biopharmaceutical company announced the pricing of an underwritten public offering that is expected to raise approximately $175 million in gross proceeds.
The offering consists of 8.25 million ordinary shares priced at $20.00 per share and pre-funded warrants to purchase 500,000 ordinary shares at $19.99 per warrant to one investor. Pharvaris has also granted underwriters a 30-day option to purchase up to an additional 1.31 million ordinary shares at the public offering price.
Morgan Stanley (NYSE:MS), Leerink Partners, Cantor, Oppenheimer & Co., and Van Lanschot (AS:VLAN) Kempen are serving as joint book-running managers for the offering, which is expected to close on or about July 24, 2025, subject to customary closing conditions.
Pharvaris specializes in developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. The company is currently conducting two pivotal Phase 3 studies for its drug candidate deucrictibant: CHAPTER-3 for prevention of hereditary angioedema attacks and RAPIDe-3 for on-demand treatment.
The shares and pre-funded warrants are being offered pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.